Article

Endocrine disruptors may explain hypospadias increase

San Francisco - Researchers have successfully induced hypospadias in mice, an accomplishment that observers say provides more compelling evidence in support of the endocrine disruptor hypothesis as an explanation for the increase in hypospadias observed over the past 30 years.

Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Patient talking with doctor | Image Credit: © bongkarn - stock.adobe.com
Shaya Taghechian, MD, answers a question during a video interview
doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Raveen Syan, MD, FPMRS, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
Vaginal estrogen for GSM not associated with major adverse cardiovascular events
October 28th 2024

Vaginal estrogen for GSM not associated with major adverse cardiovascular events

Hannah Clarke
“These findings support the safety of vaginal estrogen for treatment of local menopause symptoms, even in high-risk women,” says Gabriella M. Rustia, MD.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
Pediatric urinary microbiome composition is associated with recurrent UTI
September 10th 2024

Pediatric urinary microbiome composition is associated with recurrent UTI

Hannah Clarke
“We hope to learn more about the urinary tract and then be able to correlate predisposition to UTIs or other urological conditions with urobiome composition or marker microbe presence,” says Tatyana A. Sysoeva, PhD.
Dr. Malik evaluates quality of Reddit content on recurrent UTIs
March 17th 2022

Dr. Malik evaluates quality of Reddit content on recurrent UTIs

Urology Times staff
“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.
Collaboration to advance market launch of ProVate device for pelvic organ prolapse
September 6th 2024

Collaboration to advance market launch of ProVate device for pelvic organ prolapse

Hannah Clarke
The company expects the device to become available for US patients with pelvic organ prolapse in September 2024.
Topical sildenafil cream found safe, tolerable in female sexual arousal disorder
August 27th 2024

Topical sildenafil cream found safe, tolerable in female sexual arousal disorder

Hannah Clarke
There were no differences in the number of treatment-related TEAEs in patients who received sildenafil cream vs patients who received placebo.
© 2024 MJH Life Sciences

All rights reserved.